Welcome to our dedicated page for Silo Pharma news (Ticker: SILO), a resource for investors and traders seeking the latest updates and insights on Silo Pharma stock.
Silo Pharma Inc. (SILO) is a biopharmaceutical innovator developing novel therapies that combine traditional treatments with psychedelic research for conditions including PTSD and chronic pain. This dedicated news hub provides investors and researchers with essential updates on the company's clinical progress, strategic partnerships, and therapeutic advancements.
Access centralized, reliable information about Silo Pharma's pipeline developments, including its intranasal SPC-15 formulation for stress disorders and SP-26 implant technology for pain management. The page aggregates official press releases, research milestones, and financial disclosures while maintaining strict compliance with financial reporting standards.
Key updates cover clinical trial phases, intellectual property developments, university research collaborations, and regulatory filings. All content is verified through primary sources to ensure accuracy and timeliness for stakeholders tracking the company's progress in psychedelic-assisted therapeutics and advanced drug delivery systems.
Bookmark this page for streamlined access to Silo Pharma's latest announcements. For comprehensive tracking of the company's innovative approach to CNS disorder treatments, consider subscribing to Stock Titan's news alerts.
Silo Pharma (OTCQB: SILO) announced that its joint venture partner, Zylo Therapeutics, received DEA approval to develop Z-pod technology with Ketamine. CEO Eric Weisblum expressed optimism about creating a transdermal Ketamine therapeutic using this patented technology, which may also deliver Psilocybin in a controlled manner. This development aims to provide innovative solutions for patients suffering from depression, PTSD, Parkinson’s, and other neurological disorders. Updates on this partnership are anticipated as milestones are achieved.
Silo Pharma, Inc. (OTCQB: SILO) announced the filing of three Patent Cooperation Treaty (PCT) applications aimed at protecting its intellectual property related to the central nervous system delivery of unique anti-inflammatory therapeutics combined with psilocybin. This step is part of the company’s commitment to research and development in the biopharmaceutical space, specifically targeting conditions like depression and PTSD. The applications focus on the therapeutic potential of psychedelics and anti-inflammatory drugs, expanding possible treatment options for various neurological disorders.
On August 11, 2021, Silo Pharma (OTCQB:SILO) announced that its partner, ZYLO Therapeutics, successfully completed its first inspection with the SC Board of Pharmacy. This milestone enables progress with the Department of Health and Environmental Control towards developing a transdermal Ketamine therapeutic leveraging patented Z-Pod® technology. CEO Eric Weisblum emphasized the significance of this step, highlighting the potential for controlled, time-released delivery of Ketamine or Psilocybin.
Silo Pharma (OTCQB:SILO) announced a significant development in its product pipeline, receiving a notice of allowance for a patent from the United States Patent Office pertaining to its Central Nervous System Homing Peptide. This novel peptide aims to enhance the delivery of psychedelics, including Psilocybin, for therapeutic applications. CEO Eric Weisblum expressed optimism about expanding their intellectual property portfolio to cover markets for potential therapeutic applications, addressing conditions like depression and PTSD.
Silo Pharma, Inc. (OTCQB: SILO) will engage in a nationwide media tour on July 22, aimed at raising awareness about psychedelic medicines and their potential therapeutic benefits for conditions such as mental illness and chronic pain. Sponsored by Radio Media LLC, the tour will feature Dr. Josh Woolley, MD, PhD, discussing ongoing research in psychedelic therapy. The broadcast will reach various stations across the U.S., with recordings available on Silo Pharma's website post-event.
Silo Pharma (OTCQB: SILO) has entered into a Scientific Research Agreement with the University of Maryland, Baltimore, to investigate the efficacy of a novel peptide, ART-1, for delivering dexamethasone to treat rheumatoid arthritis. This study will utilize peptide-guided liposomes to potentially enhance the drug's efficacy and reduce toxicity. CEO Eric Weisblum emphasized the importance of this milestone for accessing a significant market and improving therapeutic targeting. The company aims to develop a technology platform adaptable for other drugs, enhancing treatment options for various conditions.
Silo Pharma has extended its exclusive option agreement with the University of Maryland, Baltimore to investigate novel joint-homing peptides aimed at treating rheumatoid arthritis. This extension allows Silo more time to evaluate a potentially transformative therapeutic platform that could enhance drug delivery for traditional and psychedelic treatments, which may improve efficacy while reducing toxicity. CEO Eric Weisblum emphasized the significance of this technology for targeted therapy delivery.
Silo Pharma, Inc. (OTCQB: SILO) has entered a Scientific Research Agreement with the University of California San Francisco (UCSF) to explore the effects of psilocybin on inflammatory markers in patients with Parkinson's, Bipolar disorder, and chronic back pain. This agreement will utilize four other planned clinical trials by UCSF. CEO Eric Weisblum emphasized the potential of psilocybin to reduce inflammation related to these conditions, which may improve treatment outcomes. The study will be conducted at UCSF's Translational Psychedelic Research Program, focusing on the impact of psychedelics on various disorders.
Silo Pharma, Inc. (OTCQB: SILO) announced the submission of its initial application to list on the NASDAQ Capital Market. This follows the board's prior approval to commence the up-listing process. The NASDAQ listing is contingent upon meeting regulatory requirements and acceptance by NASDAQ, which cannot be assured. CEO Eric Weisblum emphasized that a NASDAQ listing aims to enhance investor liquidity, attract institutional investors, and improve the company's visibility. Silo Pharma focuses on developing psychedelic therapies for conditions like depression and PTSD.
Silo Pharma, Inc. (OTCQB: SILO) announced the submission of its investigator-led study using Psilocybin for treating Parkinson’s disease for ethics board review in the Netherlands. CEO Eric Weisblum expressed satisfaction with this milestone and anticipates sharing more details with the scientific community and shareholders.
Silo Pharma is focused on merging traditional therapeutics with psychedelic research to assist patients suffering from conditions like depression, PTSD, and rare neurological disorders.
FAQ
What is the current stock price of Silo Pharma (SILO)?
What is the market cap of Silo Pharma (SILO)?
